TriSalus Life Sciences (TLSI) announced the publication of research titled, “Pressure Enabled Drug Delivery Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model,” in the peer-reviewed Journal of Vascular and Interventional Radiology. “This study further validates the potential of TriNav using the PEDD approach to transform the treatment of liver tumors. By significantly enhancing therapeutic delivery and sparing healthy tissue, PEDD offers a promising advancement for patients whose outcomes may be limited by conventional delivery methods,” said Bryan Cox, Ph.D., Chief of Research for TriSalus.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Announces Leadership Changes and New Incentive Program
- Roth expects ‘continued strong execution’ from TriSalus under new CFO
- Roth expects ‘continued strong execution’ TriSalus under new CFO
- TriSalus Life Sciences appoints James Young CFO, Richard Marshak CCO
- TriSalus Life Sciences initiated with an Overweight at Cantor Fitzgerald